97
Participants
Start Date
December 29, 2015
Primary Completion Date
August 11, 2020
Study Completion Date
August 11, 2020
INCB053914
"Initial cohort dose of INCB053914 at the protocol-specified starting dose in two treatment groups in dose escalation, with subsequent expansion in up to five cohorts based on protocol-specific criteria.~INCB053914 tablets to be administered by mouth."
I-DAC (Intermediate dose cytarabine)
Cytarabine dose will be 1 g/m\^2. Cytarabine will be administered as an intravenous (IV) infusion.
Azacitidine
Azacitidine dose will be 75 mg/m\^2. Azacitidine will be administered either sub-cutaneously (SC) or intravenously (IV).
Ruxolitinib
Starting dose of ruxolitinib will be the dose the subject was on at study entry Ruxolitinib will be administered by mouth.
University of Maryland, Baltimore
Emory University-Winship Cancer Institute, Atlanta
Mayo Clinic Florida, Jacksonville
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Florida Cancer Specialists & Research Institute, Sarasota
Tennessee Oncology, Nashville
Vanderbilt University Medical Center, Nashville
Oncology Hematology Care Clinical Trials LLC, Cincinnati
University of Michigan Comprehensive Cancer Center, Ann Arbor
Medical College of Wisconsin, Milwaukee
University of Nebraska Medical Center, Omaha
Stephenson Cancer Center, Oklahoma City
Texas Oncology, Tyler
Texas Oncology, Austin
The University of Arizona Cancer Center, Tucson
UCLA Medical Hematology & Oncology, Santa Monica
UC Davis comprehensive Cancer Center, Sacramento
Yale University, New Haven
Dana-Farber Cancer Center, Boston
Lead Sponsor
Incyte Corporation
INDUSTRY